Stellar Biotechnologies Announces Biotech Showcase 2012 Presentations

PORT HUENEME, CA--(Marketwire - Jan 4, 2012) - Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it will be making two presentations at the Biotech Showcase 2012 Conference in San Francisco January 9 - 12, 2012 at Parc 55 Wyndham - Union Square. (http://www.ebdgroup.com/bts/index.php)

This annual conference focused on public and private, small and mid-cap biotech, diagnostic, medical device and pharmaceutical companies takes place in San Francisco each year, nearby and simultaneously with the industry's largest annual healthcare conference, and is expected to draw 1500 participants, as well as many professional investors and members of the media.

The Company's CEO, Frank Oakes, is an invited participant on the "Infectious Disease Panel: Fighting the #2 Global Killer" at 8 AM on Monday, January 9th on Level 4 in the Mission 1 Room with the CEOs of four other biotechnology companies involved in vaccines and immune therapies targeting new and growing infectious threats to human health.

Importantly, Mr. Oakes will also be presenting Stellar Biotechnologies for the first time to U.S. life sciences analysts and institutional investors on January 10th at 10:30 AM in the Mission I room.

Darrell Brookstein, Stellar's Executive VP, Corporate Development & Finance, said, "As Stellar's U.S. registration is expected in the first quarter, it's important to begin the process of introducing Stellar and educating U.S. investors about the unique value and investment proposition that Stellar offers as the world's only sustainable supplier of GMP grade KLH. KLH is an essential component of many vaccines impacting cancer, infectious diseases and other indications from addiction to arthritis. We certainly expect the Biotech Showcase event to provide a dynamic platform for the Stellar story, and look forward to our first opportunity to meet potential customers and partners, as well as with the professional investors and analysts that drive financing and the markets for biopharma securities in the U.S."

Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.